Psychiatric comorbidity in patients with developmental disorders and epilepsy: A practical approach to its diagnosis and treatment

Epilepsy and Behavior

Volumn 3, Issue 6 SUPPL. 1, 2002, Pages 7-13

  Kanner, Andres M ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

Aggression; Antidepressant drugs; Antiepileptic drugs; Antipsychotic drugs; Anxiety; Autism; Depression; Intractable epilepsy; Psychosis

Indexed keywords

AMFEBUTAMONE; AMOXAPINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHLORPROMAZINE; CLOMIPRAMINE; CLOZAPINE; ETIRACETAM; FELBAMATE; FLUPHENAZINE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; MAPROTILINE; MOLINDONE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PHENOBARBITAL; PRIMIDONE; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; UNINDEXED DRUG; VENLAFAXINE; VIGABATRIN;

AKATHISIA; ANTICONVULSANT ACTIVITY; ANXIETY DISORDER; BEHAVIOR DISORDER; COMORBIDITY; DEPRESSION; DEVELOPMENTAL DISORDER; DIAGNOSTIC PROCEDURE; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG METABOLISM; DYSTONIA; ELECTROCONVULSIVE THERAPY; EPILEPSY; HUMAN; MENTAL DISEASE; REVIEW; SEIZURE; TARDIVE DYSKINESIA; TRANQUILIZING ACTIVITY;

EID: 0042385118     PISSN: 15255050     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Richardson SA, Katz M, Koller H, McLaren J, Rubinstein B. Some characteristics of a population of mentally retarded young adults in a British city: a basis for estimating some service needs. J Ment Defic Res 1979;23:275-85.
2. Borthwick-Duffy SA. Epidemiology and prevalence of psychopathology in people with mental retardation. J Consult Clin Psychol 1994;52:17-27.
3. Lund J. Epilepsy and psychiatric disorder in the mentally retarded adult. Acta Psychiatr Scand 1985;72:557-62.
4. Deb S, Hunter D. Psychopathology of people with mental handicap and epilepsy. II. Psychiatric illness. Br J Psychiatry 1991;159:826-30.
5. Ratey JJ, Dymek MP. Neuropsychiatry of mental retardation and cerebral palsy. In: Fogel BS, Schiffer RB, editors. Neuropsychiatry. Baltimore: Lippincott, Williams & Wilkins; 1996.
6. Sovner R. Limiting factors in the use of DSM-III criteria with mentally ill/mentally retarded persons. Psychopharmacol Bull 1986;22:1055-9.
7. Ratey JJ, Lindem KJ. β-Blockers as a primary treatment for aggression and self-injury in the developmentally disabled. In: Ratey JJ, editor. Mental retardation: developing pharmacotherapies. Washington, DC: American Psychiatric Press; 1991.
8. Ruedrich SL, Grush L, Wilson J. β adrenergic blocking medications for aggressive or self-injurious mentally retarded persons. Am J Ment Retard 1990;95:110-9.
9. Jankovic J, Caskey TC, Stout JT, Butler IJ. Lesch-Nyhan syndrome: a study of motor behavior and cerebrospinal fluid neurotransmitters. Ann Neurol 1988;23:466-9.
10. O'Neil M, Page N, Adkins WN, Eichelmann B. Tryptophan-trazodone treatment of aggressive behaviour. Lancet 1986;2:859-60.
11. Kanner AM, Kuzniecky R. Psychiatric phenomena as an expression of postictal and paraictal disorders. In: Ettinger AB, Kanner AM, editors. Psychiatric issues in epilepsy: a practical guide to diagnosis and treatment. Baltimore: Lippincott, Williams & Wilkins; 2000.
12. Rapin I. Autistic regression and disintegrative disorder: how important the role of epilepsy. Semin Pediatr Neurol 1995;2:278-85.
13. Kanner AM, Palac S. Depression in epilepsy: a common but often unrecognized comorbid malady. Epilepsy Behav 2000;1:37-51.
14. Kanner AM. Psychosis of epilepsy: a neurologist's perspective. Epilepsy Behav 2000;1:219-27.
15. Kanner AM. Depression and epilepsy. Neurology 1999;53(Suppl 2):S26-32.
16. Doval O, Gaviria M, Kanner AM. Frontal lobe dysfunction in epilepsy: is it responsible for its psychopathology? In: Ettinger A, Kanner AM, editors. Psychiatric issues in epilepsy: a practical guide to diagnosis and treatment. Baltimore: Lippincott, Williams & Wilkins; 2000.
17. Kanner AM, Weisbrot D. Psychiatric assessment of the epileptic patient: a non-psychiatrist perspective. In: Ettinger A, Kanner AM, editors. Psychiatric issues in epilepsy: a practical guide to diagnosis and treatment. Baltimore: Lippincott, Williams & Wilkins; 2000.
18. Robertson M. Carbamazepine and depression. Int Clin Psychopharmacol 1987;1:23-35.
19. Robertson M. Forced normalization and the aetiology of depression in epilepsy. In: Trimble MR, Schmitz B, editors. Forced normalization and alternative psychosis of epilepsy. Petersfield, UK: Wrightson Biomedical; 1998.
20. Brent DA, Crumrine PK, Varma RR, Allan M, Allman C. Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics 1987;80:909-17.
21. Ferrari M, Barabas G, Matthews WS. Psychologic and behavioral disturbance among epileptic children treated with barbiturate anticonvulsants. Am J Psychiatry 1983;140:112-3.
22. Smith DB, Mattson RH, Cramer JA, Collins JF, Novelly RA, Craft B. Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone. Epilepsia 1987;28(Suppl 3):S50-8.
23. Ring HA, Reynolds EH. Vigabatrin and behaviour disturbance. Lancet 1990;335:970.
24. McConnell H, Duffy J, Cress K. Behavioral effects of felbamate. J Neuropsychiatry Clin Neurosci 1994;6:323.
25. Shorvon SD. Safety of topiramate: adverse events and relationship to dosing. Epilepsia 1996;37(Suppl 2):S18-22.
26. Sadek AH, Kanner AM, Montouris G, Fix A, French JA. Behavioral adverse events in patients taking levetiracetam. Neurology 2002;(Suppl 3):A297.
27. Wolf SM, Shinnar S, Kang H, Gil KB, Moshe SL. Gabapentin toxicity in children manifesting as behavioral changes. Epilepsia 1995;36:1203-5.
28. Beran RG, Gibson RJ. Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine. Epilepsia 1998;39:280-2.
29. Ettinger AB, Weisbrot DM, Saracco J, Dhoon A, Kanner A, Devinsky O. Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. Epilepsia 1998;39:874-7.
30. Blanchet P, Frommer GP. Mood change preceding epileptic seizures. J Nerv Ment Dis 1986;174:471-6.
31. Kanner AM, Stagno S, Kotagal P, Morris HH. Postictal psychiatric events during prolonged video-electroencephalographic monitoring studies. Arch Neurol 1996;53:258-63.
32. Logsdail SJ, Toone BK. Post-ictal psychoses: a clinical and phenomenological description. Br J Psychiatry 1988;152:246-52.
33. Savard G, Andermann F, Olivier A, Remillard GM. Postictal psychosis after partial complex seizures: a multiple case study. Epilepsia 1991;32:225-31.
34. Devinsky O, Abramson H, Alper K, et al. Postictal psychosis: a case control series of 20 patients and 150 controls. Epilepsy Res 1995;20:247-53.
35. Umbricht D, Degreef G, Barr WB, Lieberman JA, Pollack S, Schaul N. Postictal and chronic psychoses in patients with temporal lobe epilepsy. Am J Psychiatry 1995;152:224-31.
36. Neill JC, Alvarez N. Differential diagnosis of epileptic versus pseudoepileptic seizures in developmentally disabled persons. Appl Res Ment Retard 1986;7:285-98.
37. Beaumanoir A. The Landau-Kleffner syndrome. In: Roger J, Dravet C, Bureau M, Dreifuss FE, Wolf P, editors. Epileptic syndromes in infancy, childhood and adolescence. London: John Libbey Eurotext; 1985.
38. Rosenstein DL, Nelson JC, Jacobs SC. Seizures associated with antidepressants: a review. J Clin Psychiatry 1993;54:289-99.
39. McConnell H, Duncan D. Treatment of psychiatric comorbidity in epilepsy. In: McConnell H, Snyder P, editors. Psychiatic comorbidity in epilepsy: basic mechanisms, diagnosis and treatment. Washington, DC: American Psychiatric Press; 1998.
40. Curran S, de Pauw K. Selecting an antidepressant for use in a patient with epilepsy: safety considerations. Drug Saf 1998;18:125-33.
41. Swinkels JA, de Jonghe F. Safety of antidepressants. Int Clin Psychopharmacol 1995;9(Suppl 4):19-25.
42. Spiller HA, Ramoska E, Krenzelok EP, et al. Bupropion overdose: a 3-year multi-center retrospective analysis. Am J Emerg Med 1994;12:43-5.
43. Logothetis J. Spontaneous epileptic seizures and electroencephalographic changes in the course of phenothiazine therapy. Neurology 1967;17:869-77.
44. Toth P, Frankenburg FR. Clozapine and seizures: a review. Can J Psychiatry 1994;39:236-8.
45. Pacia SV, Devinsky O. Clozapine-related seizures: experience with 5629 patients. Neurology 1994;44:2247-9.
46. Owen Jr RR, Cole JO. Molindone hydrochloride: a review of laboratory and clinical findings. J Clin Psychopharmacol 1989;9:268-76.
47. Gualtieri CT, Schroeder SR, Hicks RE, Quade D. Tardive dyskinesia in young mentally retarded individuals. Arch Gen Psychiatry 1986;43:335-40.
48. Tollefson GD, Rosenbaum JF. Selective serotonin reuptake inhibitors. In: Schatzberg AF, Nemeroff CB, editors. Textbook of psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press; 1998.
49. Kanner AM, Kozac AM, Frei M. The use of sertraline in patients with epilepsy: is it safe? Epilepsy Behav 2000;1:100-5.
50. Bell AJ, Cole A, Eccleston D, Ferrier IN. Lithium neurotoxicity at normal therapeutic levels. Br J Psychiatry 1993;162:689-92.
51. Wolf ME, Caro M, Mosnaim AD. Lithium neuroleptic interactions: electroencephalographic studies. Res Commun Psychol Psychiatry Behav 1991;16:35-40.
52. Blackwood DH, Cull RE, Freeman CP, Evans JI, Mawdsley C. A study of the incidence of epilepsy following ECT. J Neurol Neurosurg Psychiatry 1980;43:1098-102.
53. Abrams R. Electroconvulsive therapy in the high-risk patient. In: Abrams R, editor. Electroconvulsive therapy. New York: Oxford University Press; 1997.
54. Stahl SM. "Hit-and-Run" actions at dopamine receptors. Part 1: Mechanism of action of atypical antipsychotics. J Clin Psychiatry 2001;62:670-1.
55. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16:23-45.
56. Ratey J, Sovner R, Parks A, Rogentine K. Buspirone treatment of aggression and anxiety in mentally retarded patients: a multiple-baseline, placebo lead-in study. J Clin Psychiatry 1991;52:159-64.
57. Barry JJ, Huynh N. Psychotropic drug use in patients with epilepsy and developmental disabilities. In: Devinsky O, Westbrook LE, editors. Epilepsy and developmental disabilities. Burlington: Butterworth-Heinemann; 2002.
58. Silver JM, Yudofsky SC, Slater JA, et al. Propranolol treatment of chronically hospitalized aggressive patients. J Neuropsychiatry Clin Neurosci 1999;11:328-35.
59. Schatzberg AF, Cole JO, DeBattista C. Manual of clinical psychopharmacology. third ed. Washington, DC: American Psychiatric Press; 1997.
60. Gross-Tsur V, Manor O, van der Meere J, Joseph A, Shalev RS. Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? J Pediatr 1997;130:670-4.
61. Wroblewski BA, Leary JM, Phelan AM, Whyte J, Manning K. Methylphenidate and seizure frequency in brain injured patients with seizure disorders. J Clin Psychiatry 1992;53:86-9.
62. Herman BH, Hammock MK, Egan J, et al. Naltrexone induces dose-dependent decreases in self-injurious behavior. Soc Neurosci Abstr 1985;11:468.